Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Iovance Biotherapeutics (IOVA) over the last 9 years, with Q3 2025 value amounting to $9.9 million.

  • Iovance Biotherapeutics' Treasury Shares fell 31.45% to $9.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.9 million, marking a year-over-year decrease of 31.45%. This contributed to the annual value of $9.5 million for FY2024, which is 17643.07% up from last year.
  • Per Iovance Biotherapeutics' latest filing, its Treasury Shares stood at $9.9 million for Q3 2025, which was down 31.45% from $11.4 million recorded in Q2 2025.
  • Iovance Biotherapeutics' Treasury Shares' 5-year high stood at $12.2 million during Q1 2025, with a 5-year trough of $3.5 million in Q4 2023.
  • Moreover, its 3-year median value for Treasury Shares was $9.9 million (2025), whereas its average is $8.4 million.
  • As far as peak fluctuations go, Iovance Biotherapeutics' Treasury Shares skyrocketed by 20893.41% in 2024, and later plummeted by 360.33% in 2025.
  • Over the past 3 years, Iovance Biotherapeutics' Treasury Shares (Quarter) stood at $3.5 million in 2023, then skyrocketed by 176.43% to $9.5 million in 2024, then rose by 3.53% to $9.9 million in 2025.
  • Its last three reported values are $9.9 million in Q3 2025, $11.4 million for Q2 2025, and $12.2 million during Q1 2025.